Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 4/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033027 | 0.91 | ALDH1A1 (0.50) | IL2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5034885 | 0.91 | IL2 (0.48) | IL2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5031522 | 0.88 | RAB9A (0.45) | IL2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5028448 | 0.88 | IL2 (0.52) | IL2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5028502 | 0.87 | CYP3A4 (0.48) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5033039 | 0.87 | NPC1 (0.44) | IL2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5030724 | 0.87 | IL2 (0.50) | IL2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8227368 | 0.87 | IL2 (0.45) | IL2MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5028493 | 0.86 | SMN1; SMN2 (0.50) | IL2RAB9ASMN1; SMN2KDM4EHPGD | |
| SCHEMBL5032990 | 0.86 | TERT (0.45) | IL2MAPK14NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | claimed |
| EP-1998612-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-10 | — | — | EP | claimed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2007087442-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1998612-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007087442-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | CCR1, CCR3, CXCR2 | IL2 5/4885MAPK14 3571/4885NPC1 477/4885 |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR3, CXCR2 | IL2 5/4885MAPK14 3571/4885NPC1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.